IL6 and neoplasm: The significance of the TME for MCL progression is illustrated by the observation that treatment of the Jeko-1 MCL cell line with anti-CXCR4 and anti-VLA-4 antibodies reduced cross talk between the tumor cells and stromal cells, decreased IL6 levels and phosphorylation of ERK1/2, AKT, and NF-κB, and increased the therapeutic sensitivity of Jeko-1 [32].